The Zhitong Finance App learned that City Therapeutics Inc. (CTY.US), an early-stage RNAi drug developer, is seeking to raise up to $184.7 million in a US initial public offering (IPO). The investor, which includes companies from Arch Venture Partners and Fidelity Management Research, plans to issue 9.72 million shares at a price of $17 to $19 per share, according to the company's filing with the US Securities and Exchange Commission on Friday.

The Zhitong Finance App learned that City Therapeutics Inc. (CTY.US), an early-stage RNAi drug developer, is seeking to raise up to $184.7 million in a US initial public offering (IPO). The investor, which includes companies from Arch Venture Partners and Fidelity Management Research, plans to issue 9.72 million shares at a price of $17 to $19 per share, according to the company's filing with the US Securities and Exchange Commission on Friday.